| Code | CSB-RA023981MB11HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ivuxolimab, targeting TNFRSF4 (tumor necrosis factor receptor superfamily member 4), also known as OX40 or CD134. TNFRSF4 is a co-stimulatory receptor primarily expressed on activated T cells that plays a critical role in T cell activation, proliferation, and survival. Upon binding to its ligand OX40L, TNFRSF4 enhances T cell-mediated immune responses and promotes the generation of memory T cells. This receptor is particularly relevant in cancer immunology and autoimmune diseases, as it regulates the balance between effector T cells and regulatory T cells, making it an important therapeutic target for modulating immune responses in oncology and inflammatory conditions.
Ivuxolimab is an investigational agonistic antibody designed to stimulate anti-tumor immunity by activating the OX40 pathway, thereby enhancing T cell responses against cancer cells. This biosimilar antibody serves as a valuable research tool for studying TNFRSF4-mediated immune regulation, T cell biology, checkpoint modulation, and immune-oncology mechanisms. It enables researchers to investigate therapeutic strategies targeting the OX40/OX40L axis in various disease models.
There are currently no reviews for this product.